Diagnosis of pulmonary lymphangitic carcinomatosis is considered to represent end-stage malignancy, with the life expectancy being about six months. However, reports of survival up to 3 years and more have also been reported with currently available management.

Bruce et al. observed death within three months of presentation of respiratory symptoms in half of the patients, and Zhang et al. noted that almost 72% of the patients died within seven months of presentation.